AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05209659 — intervention group
Intervention type: OTHER
Intervention: Pragmatic Mobilization
Description: The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.~Other Name: Non-thrust manipulation (pragmatically applied)
Study NCT04839744 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TG103 produced by the modified manufacturing process
Description: Drug: TG103 (a modified manufacturing process), 15mg, SC
Study NCT04839744 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TG103 produced by the original manufacturing process
Description: Drug: TG103 (the original manufacturing process), 15mg, SC
Study NCT04864743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADVATE
Description: a single dose.
Study NCT04864743 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FRSW117
Description: a single dose.
Study NCT06206512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Extended release torsemide
Description: This is an extended-release formulation of torsemide
Study NCT06206512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Immediate release torsemide
Description: This is the generic, immediate release formulation of torsemide
Study NCT06206512 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Extended release torsemide placebo
Description: Placebo of extended release torsemide
Study NCT06206512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate release torsemide placebo
Description: Placebo of immediate release torsemide
Study NCT04710212 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: Observational study with no intervention.
Study NCT05686655 — intervention group
Intervention type: OTHER
Intervention: questionnaire about sleep quality in diabetic children
Description: Pittsburgh sleep quality index
Study NCT06527599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid Risk Monitoring (ORM)
Description: A brief battery of self-reported screeners for risk factors associated with opioid misuse (e.g., Current Opioid Misuse Measure; Pain, Enjoyment of life, and General activities scale; Pain Catastrophizing Scale). These measures will be administered within seven days of hospital discharge (i.e., baseline), and again at 2-, 4-, 8-, and 12-weeks following discharge to assess for ongoing risk for opioid misuse. Participants will additionally complete the self-reported Opioid Risk Tool within seven days of hospital discharge.
Study NCT06527599 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Opioid Risk Monitoring (ORM)
Description: A brief battery of self-reported screeners for risk factors associated with opioid misuse (e.g., Current Opioid Misuse Measure; Pain, Enjoyment of life, and General activities scale; Pain Catastrophizing Scale). These measures will be administered within seven days of hospital discharge (i.e., baseline), and again at 2-, 4-, 8-, and 12-weeks following discharge to assess for ongoing risk for opioid misuse. Participants will additionally complete the self-reported Opioid Risk Tool within seven days of hospital discharge.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: enhanced Trauma Care Coordination (eTCC)
Description: An enhanced care management model with increased patient contact and embedded interventions based on clinical presentation and collaboration with the patient. eTCC is a telehealth-based care coordinating intervention where a care coordinator assesses the participant, creates a plan of care, collaborates with the eTCC team, follows up with a second virtual visit within a week, and communicates with the participant and care team at least bi-weekly for the 3 month intervention period.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training - Brief (PCST-LITE)
Description: PCST-LITE will consist of a single 55-minute videoconference session, in which participants will receive brief psychoeducation grounded in gate control theory, progressive muscle relaxation (PMR), and therapist-guided imagery. Participants will be asked to practice PMR and imagery daily and will receive four weeks of regular (4-5 times per week) text messaging as a reminder.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Trauma Care Coordination (sTCC)
Description: Standard Trauma Care Coordination (sTCC) will functionally serve as a treatment-as-usual arm, as it will involve no study intervention.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Trauma Care Coordination (sTCC)
Description: Standard Trauma Care Coordination (sTCC) will functionally serve as a treatment-as-usual arm, as it will involve no study intervention.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training - Plus (PCST+)
Description: PCST+ will include two videoconferencing sessions, in addition to the first videoconferencing session they previously received. In session 1, participants will be taught an activity/rest cycle to schedule activities, so they are productive while avoiding increasing pain severity due to taking insufficient breaks. Session 2 centers around cognitive restructuring, involving brief psychoeducation and skills development surrounding how participants might recognize the influence that cognitions can have on pain intensity and coping. Participants will receive 3 weekly, 15-minute calls to review skills and problem-solve.
Study NCT06527599 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training - Maintenance (PCST-M)
Description: PCST-M consists of five weekly booster calls from the patient's study therapist to reinforce the techniques covered in the initial PCST-Lite session.
Study NCT06044818 — intervention group
Intervention type: DEVICE
Intervention: Accexible
Description: Speech Analysis
Study NCT06139172 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Functional Behavioral Training (FBT)
Description: Function-based treatment (FBT) is a term for behavioral intervention approaches that use objective and systematic data collection to identify the cause of challenging behavior and teach a more prosocial replacement behavior. FBTslDD incorporates standard elements of FBT protocols with adaptations made specifically to support application to the syndromic IDD population. FBTslDD will include the following steps: (1) Syndromic IDD screening; (2) Stimulus preference assessment; (3) Indirect and descriptive assessments; (4) Screening for automatic function; (5) Functional analysis (FA); and (6) FBT intervention phase. If steps 1 - 5 determine a participant's challenging behavior serves a social function, Functional Communication Training (FCT) will be administered. If steps 1 - 5 determine a participant's challenging behavior serves an automatic function Competing Stimulus Treatment (CST) will be administered.
Study NCT06139172 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Parenting Strategies-Treatment as Usual
Description: Using the Planned Adaptation approach, to identify proactive adaptations seeking to improve the fit of FBTsIDD with the unique needs of the syndromic IDD population. Triangulating mixed methods data from systematic video observations, questionnaires, and qualitative interviews, then the Framework for Reporting Adaptations and Modifications-Expanded24 (FRAME) will be used to develop a rich understanding of these and any additional adaptations made to the intervention when delivered by non-specialist providers within medical hubs serving syndromic IDD populations.
Study NCT05474183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: drug
Study NCT05474183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: drug
Study NCT05656170 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Stellate ganglion block
Description: Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total).
Study NCT05656170 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Ultrasound will be utilized to identify anatomic landmarks and prepare for the stellate ganglion block. Skin will be prepped with chloraprep. The C6 level is identified. The Chassaignac tubercle (the anterior tubercle of the C6 vertebral body) is then identified. Placement of the ultrasound transducer helps retract the carotid sheath and sternocleidomastoid muscle laterally. Pressure is applied with the ultrasound transducer to reduce the distance between the skin and tubercle.~The needle is inserted towards to the Chassaignac tubercle after contact it is redirected towards the body of C6. The needle is then withdrawn 1-2 mm to bring it out of the longus colli muscle while still staying within the prevertebral fascia. After negative aspiration, 1-2 mL of local anesthetic (or normal saline in the placebo group) is injected, and spread can be visualized with ultrasound. Once confirming that the injection was subfascial, the remaining local anesthetic can be given (10 mL in total).
Study NCT05656170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The intervention group will receive bupivacaine injection guided by ultrasound at the location of the stellate ganglion.
Study NCT05656170 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: The control group will receive a normal saline injection guided by ultrasound at the location of the stellate ganglion.
Study NCT02960737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral neuromuscular training using an oral device
Description: The oral device is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial and pharyngeal muscles.
Study NCT06244576 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Radically Open Dialectical Behaviour Therapy (RO-DBT)
Description: RO-DBT is a trans diagnostic intervention specifically designed to treat a spectrum of disorders characterized by excessive overcontrol such as anorexia nervosa, autism spectrum disorder, refractory depression, cluster c personality disorders, and mood disorders.
Study NCT05672901 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StrataMGT
Description: StrataMGT is a 100% medical grade film-forming silicone gel for the treatment of cutaneous skin lesions and Genitourinary Syndrome of Menopause. StrataMGT is a flexible wound dressing used on compromised skin. It dries to form a thin, flexible wound dressing which hydrates and protects affected areas. StrataMGT is used to relieve low grade inflammatory changes such as dry, itching, flaking, peeling and irritated skin. StrataMGT is designed for partially epithelized skin and is suitable for children and patients with sensitive skin.
Study NCT05672901 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrace 0.01% Vaginal Cream
Description: Estrace is a prescriptive female hormone indicated in the treatment of moderate to severe symptoms of Genitourinary Syndrome of Menopause.
Study NCT05428995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: C-MAC videolaryngoscope
Description: Patients with anticipated difficult airway will be awake intubated with a C-MAC videolaryngoscopy
Study NCT05428995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airtraq videolaryngoscope.
Description: Patients with anticipated difficult airway will be awake intubated with a Airtraq videolaryngoscopy
Study NCT04774653 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Associations and prevalence will be calculated
Study NCT05911373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: group serratus plan block
Description: preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml saline
Study NCT05911373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: group serratus and parasternal plan block
Description: preoperativelly, Superficial Serratus Block performed with 30 ml %0.25 Bupivacaine and Parasternal Block performed with 10 ml %0.25 Bupivacaine
Study NCT05265325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules TIW
Description: Orally, 3 times per week in Period 1 and dose adjustment in Period 2 at 2 mg/4 mg and 2-weeks interval according to Hb levels
Study NCT05265325 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017 capsules QW
Description: Orally, once per week in Period 1 and dose adjustment in Period 2 at 4 mg/8 mg and 2-weeks interval according to Hb levels
Study NCT05265325 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epoetin alfa, darbepoetin alfa, Mircera®, or their biosimilars
Description: Dose regimen and adjustment rules according to the USPI or SmPC or local practice
Study NCT05538884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intertransverse process block
Description: The ITPB block at T5-6 will be performed with a mixture of local anesthetic with MRI contrast 0.5% bupivacaine 10 ml and 0.5 ml contrast in concentration 3.09 mmol/l. Volunteers will be moved to MRI machine and imaged in a supine position for their whole thoracic spine. This process will last about 45-60 minutes.
Study NCT04911959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib is taken orally.
Study NCT04911959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: TACE treatment once.
Study NCT04911959 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: TACE treatment once.
Study NCT05618314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: single dose AT-527
Study NCT05618314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527
Description: Single dose of AT-527 pre- and post-dialysis
Study NCT05618314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AT-527 and Probenecid
Description: Single dose of AT-527 on Days 1 and 15. Probenecid administered twice daily (BID) Days 14-19
Study NCT02870647 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire
Description: each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active A
Description: Powdered formula containing whey protein and arginine
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active A
Description: Powdered formula containing whey protein and arginine
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Active B
Description: Powdered formula containing whey protein
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lipid bolus
Description: Omega-3 fatty acids
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: Control placebo oil that does not contain omega-3 fatty acids
Study NCT04549662 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oil
Description: Control placebo oil that does not contain omega-3 fatty acids
Study NCT06195436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy for people with and without depression
Description: Participants with and without depression will be assigned to two study groups; both groups will undergo Acceptance and Commitment Therapy based on the required guidelines for twelve weeks.
Study NCT06213558 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rectangular and square striaght archwire technique
Description: The Effect of Rectangular Versus Square Archwire on Maxillary Canine Retraction
Study NCT04802499 — intervention group
Intervention type: PROCEDURE
Intervention: Turkish Reliability and Validity of TESS
Description: Translation and cultural adaptation of the scale will be designed according to the appropriate procedure. Turkish data will be uploaded in the online online method. The scale will be communicated online to those who have received telerehabilitation services, caregivers and healthcare professionals who have applied it. The reliability of the questionnaire will be made by test-retest and internal consistency analysis. Volunteers will be asked to answer the questionnaire online after 5 days. After two weeks, the participants will be asked to answer the questionnaire again with the same method online with 5 days intervals. After all data are collected, validity analysis will be performed
Study NCT04806022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fatigability assessment
Description: Each participant will do both types of fatigue over 2 appointments spaced by 7 days so that the subject can recover from induced fatigue. The sequence of fatigue tasks will be randomized.
Study NCT05104385 — intervention group
Intervention type: OTHER
Intervention: Observational, prospective, follow-up of the recipients of CoronaVac (inactivated), Pfizer-Biontech (mRNA) vaccines
Description: Based on the Turkish Ministry of Health regulations, any research protocol involving use of any drug/vaccine needs to be presented in a clinical trial format, and is presented to the clinical research ethical boards accordingly. Otherwise, the study has no intervention (to the exposure status) involved. Selection, administration, number of doses applied and the period between vaccine doses are beyond the capacity the study team.
Study NCT05758896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isuzinaxib (APX-115)
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Study NCT05758896 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment allocation in 1:1 ratio to Isuzinaxib or Placebo
Study NCT06434935 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: CABA
Description: Coronary Bypass
Study NCT06169462 — intervention group
Intervention type: PROCEDURE
Intervention: PENG block
Description: Patients underwent ultrasound-guided PENG Block for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
Study NCT06169462 — intervention group
Intervention type: PROCEDURE
Intervention: PENG block+ SIFCB
Description: Patients underwent ultrasound-guided PENG Block+ SIFCB for older adult patients surgery for hip fracture. Patients who received opioids as a rescue analgesic during postoperative pain management on selected dates will be included in the study.
Study NCT04939701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP0739
Description: Intravenous (IV)
Study NCT00013260 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Integrated model of primary care
Study NCT06063928 — intervention group
Intervention type: PROCEDURE
Intervention: Archive Sample Retrieval
Description: Undergo collection of archival tumor tissue
Study NCT06063928 — intervention group
Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo stool and blood sample collection
Study NCT06063928 — intervention group
Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Medical records reviewed
Study NCT06063928 — intervention group
Intervention type: OTHER
Intervention: Genetic Testing
Description: Undergo genetic testing
Study NCT06063928 — intervention group
Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study NCT04851106 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Endoscopic ultrasound
Description: Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.
Study NCT05701813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: INOSITOLS
Description: 4000 mg of myo-inositol and 300 mg of D-chiro-inositol. Once a day for 90 days.
Study NCT05701813 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: CELLULOSE
Description: 4.3 grams of cellulose once a day for 90 days.